We hypothesized that the effect of erythropoietin may be reflected by changes in thromboxane
B2 (TXB2) and endothelial cell function.
Six male and six female subjects received recombinant human epoetin alpha (Erypo®)
intravenously (300 Units per kg). Biomarker levels were assessed at baseline and 4, 24, 48
and 72 hours after administration.